AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% UpsideSeeking Alpha • 11/30/20
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare ConferenceGlobeNewsWire • 11/13/20
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline UpdatesGlobeNewsWire • 11/04/20
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)Insider Monkey • 10/26/20
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)GlobeNewsWire • 10/13/20
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare ConferenceGlobeNewsWire • 09/11/20
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline UpdatesGlobeNewsWire • 08/10/20
AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular PsoriasisGlobeNewsWire • 07/08/20
AnaptysBio, Inc. (ANAB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/22/20
ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The FirmPRNewsWire • 05/19/20
ANAPTYSBIO LOSS NOTICE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Reminds AnaptysBio, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ANABPRNewsWire • 05/15/20